Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus tablets for benign lymphatic endothelioma
ChiCTR2200065756Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in Benign lymphangioendothelioma (BLE), sponsored by Xijing Hospital. Primary endpoints: Clinical lesion score and Dermatology Quality of Life Index (DLQI) score. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
Benign lymphangioendothelioma (BLE)
Beyond the preview
Go deeper on ChiCTR2200065756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065756.